Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.[Arch Gen Psychiatry. 2011]

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W

Arch Gen Psychiatry. 2011 Dec; 68(12):1238-46.
Review Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.[Cochrane Database Syst Rev. 2009]

Mattick RP, Breen C, Kimber J, Davoli M

Cochrane Database Syst Rev. 2009 Jul 8; (3):CD002209.
Review Opioid agonist treatment for pharmaceutical opioid dependent people.[Cochrane Database Syst Rev. 2016]

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N

Cochrane Database Syst Rev. 2016 May 9; (5):CD011117.

A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.[JAMA. 1965]

DOLE VP, NYSWANDER M

JAMA. 1965 Aug 23; 193():646-50.
Methadone maintenance treatment for 25,000 heroin addicts.[JAMA. 1971]

Dole VP

JAMA. 1971 Feb 15; 215(7):1131-4.
Review Oral substitution treatment of injecting opioid users for prevention of HIV infection.[Cochrane Database Syst Rev. 2011]

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R

Cochrane Database Syst Rev. 2011 Aug 10; (8):CD004145.
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.[JAMA Intern Med. 2014]

Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K

JAMA Intern Med. 2014 Dec; 174(12):1974-81.

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.[Arch Gen Psychiatry. 1978]

Jasinski DR, Pevnick JS, Griffith JD

Arch Gen Psychiatry. 1978 Apr; 35(4):501-16.

Review Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?[Drug Alcohol Depend. 2003]

Mendelson J, Jones RT

Drug Alcohol Depend. 2003 May 21; 70(2 Suppl):S29-37.

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.[Lancet. 2003]

Kakko J, Svanborg KD, Kreek MJ, Heilig M

Lancet. 2003 Feb 22; 361(9358):662-8.
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.[N Engl J Med. 2003]

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D, Buprenorphine/Naloxone Collaborative Study Group.

N Engl J Med. 2003 Sep 4; 349(10):949-58.
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.[Drug Alcohol Depend. 2010]

Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG

Drug Alcohol Depend. 2010 Jan 1; 106(1):56-60.

Review Opioid agonist treatment for pharmaceutical opioid dependent people.[Cochrane Database Syst Rev. 2016]

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N

Cochrane Database Syst Rev. 2016 May 9; (5):CD011117.
Review Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.[BMJ. 2017]

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R

BMJ. 2017 Apr 26; 357():j1550.
Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.[J Psychoactive Drugs. 2015]

Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, Jaffe JH

J Psychoactive Drugs. 2015 Apr-Jun; 47(2):149-57.
Review Oral substitution treatment of injecting opioid users for prevention of HIV infection.[Cochrane Database Syst Rev. 2011]

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R

Cochrane Database Syst Rev. 2011 Aug 10; (8):CD004145.
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.[JAMA Intern Med. 2014]

Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K

JAMA Intern Med. 2014 Dec; 174(12):1974-81.
Retention in buprenorphine treatment is associated with improved HCV care outcomes.[J Subst Abuse Treat. 2017]

Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO

J Subst Abuse Treat. 2017 Apr; 75():38-42.

Review Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.[Cochrane Database Syst Rev. 2008]

Mattick RP, Kimber J, Breen C, Davoli M

Cochrane Database Syst Rev. 2008 Apr 16; (2):CD002207.
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.[Addiction. 2014]

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W

Addiction. 2014 Jan; 109(1):79-87.
Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.[Addiction. 2016]

Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W

Addiction. 2016 Apr; 111(4):695-705.
Review Medication-assisted treatment with buprenorphine: assessing the evidence.[Psychiatr Serv. 2014]

Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME

Psychiatr Serv. 2014 Feb 1; 65(2):158-70.
Comparing overdose mortality associated with methadone and buprenorphine treatment.[Drug Alcohol Depend. 2009]

Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P

Drug Alcohol Depend. 2009 Sep 1; 104(1-2):73-7.
Review New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.[Subst Abuse Rehabil. 2015]

Soyka M

Subst Abuse Rehabil. 2015; 6():1-14.

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.[Lancet. 2008]

Schottenfeld RS, Chawarski MC, Mazlan M

Lancet. 2008 Jun 28; 371(9631):2192-200.
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.[J Subst Abuse Treat. 2018]

Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY

J Subst Abuse Treat. 2018 Feb; 85():90-96.
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.[J Subst Abuse Treat. 2016]

Crits-Christoph P, Markell HM, Gibbons MB, Gallop R, Lundy C, Stringer M, Gastfriend DR

J Subst Abuse Treat. 2016 Nov; 70():50-57.
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.[JAMA Psychiatry. 2017]

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N

JAMA Psychiatry. 2017 Dec 1; 74(12):1197-1205.
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.[Lancet. 2018]

Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J

Lancet. 2018 Jan 27; 391(10118):309-318.
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).[Addiction. 2004]

Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP, NEPOD Research Group.

Addiction. 2004 Apr; 99(4):450-60.

Review Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.[Addiction. 2016]

Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, Jones HE

Addiction. 2016 Dec; 111(12):2115-2128.
Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations.[AJP Rep. 2016]

Wiegand SL, Swortwood MJ, Huestis MA, Thorp J, Jones HE, Vora NL

AJP Rep. 2016 Oct; 6(4):e385-e390.
Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population.[BMJ Open. 2016]

Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, Kelly L

BMJ Open. 2016 Oct 31; 6(10):e011774.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.[Arch Gen Psychiatry. 2011]

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W

Arch Gen Psychiatry. 2011 Dec; 68(12):1238-46.
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.[JAMA. 2008]

Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P

JAMA. 2008 Nov 5; 300(17):2003-11.

Review The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.[Am J Psychiatry. 2017]

Carroll KM, Weiss RD

Am J Psychiatry. 2017 Aug 1; 174(8):738-747.
Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?[Drug Alcohol Depend. 2014]

Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM

Drug Alcohol Depend. 2014 Jul 1; 140():118-22.

Geographic and specialty distribution of US physicians trained to treat opioid use disorder.[Ann Fam Med. 2015]

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH

Ann Fam Med. 2015 Jan-Feb; 13(1):23-6.
Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.[J Addict Med. 2017]

Brooklyn JR, Sigmon SC

J Addict Med. 2017 Jul/Aug; 11(4):286-292.
Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.[JAMA. 2015]

D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA

JAMA. 2015 Apr 28; 313(16):1636-44.

Medication-Assisted Opioid Treatment Prescribers in Federally Qualified Health Centers: Capacity Lags in Rural Areas.[J Rural Health. 2018]

Jones EB

J Rural Health. 2018 Dec; 34(1):14-22.
Geographic and specialty distribution of US physicians trained to treat opioid use disorder.[Ann Fam Med. 2015]

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH

Ann Fam Med. 2015 Jan-Feb; 13(1):23-6.
Factors affecting willingness to provide buprenorphine treatment.[J Subst Abuse Treat. 2009]

Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA, BHIVES Collaborative.

J Subst Abuse Treat. 2009 Apr; 36(3):244-51.

Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.[J Subst Abuse Treat. 2015]

Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O'Grady KE, Jaffe JH

J Subst Abuse Treat. 2015 Oct; 57():89-95.

Review New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.[Subst Abuse Rehabil. 2015]

Soyka M

Subst Abuse Rehabil. 2015; 6():1-14.

Review A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.[J Addict Med. 2014]

Lofwall MR, Walsh SL

J Addict Med. 2014 Sep-Oct; 8(5):315-26.
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.[J Addict Med. 2011]

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND

J Addict Med. 2011 Sep; 5(3):175-80.

Save items

Similar articles in PubMed

Cited by other articles in PMC

Links

Recent Activity